Cancer

February 3, 2019

Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) (MAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene, 3/February/2019, 10.58 pm

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, […]
February 3, 2019

Combinatorial therapy for glioblastoma: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) [MAN] inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down-regulation of its target gene, 3/February/2019, 10.39 pm

Introduction: What they say:  A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors […]
January 31, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing   MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CADM1, BIRC5, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 31/January/2019, `10.44 pm

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem cells […]
January 30, 2019

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  BTG2, SMARCA4, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 30/January/2019, `7.38 pm

What we say: Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports here that: Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic […]